Anti-FAM19A5 Antibody CDR Design for Specific Target Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for antibodies that specifically bind to FAM19A5 to modulate its activity, as it plays a role in regulating immune cells and is implicated in fibrosis and cancer, particularly in the central nervous system and brain tumors like glioblastoma, with existing treatments being inadequate.
Innovation Solution
Development of anti-FAM19A5 antibodies with specific CDR sequences that bind to FAM19A5 epitopes, reducing fibrosis, tumor growth, and modulating neural activity, including chimeric and humanized antibodies with high affinity and specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for fibrosis and cancer, then general treatment is provided, but specific modulation of FAM19A5 activity is inadequate
Solution Approach 1:
The patent introduces anti-FAM19A5 antibodies as intermediary molecules that specifically bind to the FAM19A5 protein, thereby mediating the modulation of FAM19A5 activity. These antibodies serve as the connecting element between the therapeutic agent and the target protein, enabling specific treatment of fibrosis and cancer by blocking or modulating FAM19A5 function without affecting other proteins
2Measurement precision
If antibodies with high specificity to FAM19A5 are developed, then specific binding is achieved, but complexity of antibody design increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody into its functional components: variable regions (VH and VL) that provide specificity through complementarity determining regions (CDRs), and constant regions that provide structural stability. By designing and optimizing specific CDR sequences (CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, CDR-L3) while using standardized framework regions, the patent achieves high binding specificity without unnecessary overall complexity
Solution Approach 2:
The patent creates chimeric and humanized antibody constructs that can be produced in mammalian cell lines with consistent quality attributes. The standardized constant regions and modular variable region design allow these antibodies to serve multiple functions: specific binding to FAM19A5, eliciting immune responses, and being manufactured reproducibly across different batches and production systems
Data Source
AI summary
The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. Also provided herein are methods for treating fibrosis or cancer using the anti-FAM19A5 antibodies.